Search
Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years
ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.
Read moreEHA European Hematology Exam 2018 Report
1. Method
a. Format
The second European Hematology Exam took place on Wednesday, June 13 in Stockholm, Sweden, and Bern, Switzerland. The Exam consisted of 100 multiple choice questions, covering all eight sections of the European Hematology Curriculum.
EHA Statement on COVID-19
The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).
Read moreRegistration & Accommodation
Registration is now closed. Registration fee includes:
Access to the scientific and educational sessions of the meeting
Networking opportunities during breaks and welcome reception
Catering during meeting hours incl.
Call for interest
As a member of an EHA committee or taskforce, you’ll be instrumental in taking our ambitions to the next level.
Read more